World's Best Scientists 2026 revealed!

H. Suryapranata publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where H. Suryapranata sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

The last bar groups every scientist with 1,796 publications or more.

H. Suryapranata D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where H. Suryapranata sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

The last bar groups every scientist with 217 D-Index or more.

Overview

H. Suryapranata is affiliated with Radboud University Medical Center in the Netherlands. Their research primarily focuses on the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with significant contributions within subfields such as Genetics, Oncology, Pathology and Forensic Medicine, Molecular Biology, and Cancer Research.

Their work extensively covers topics related to colorectal cancer, including genetic factors, genetic associations and epidemiology, colorectal cancer screening and detection, as well as aspects concerning cancer, lipids, and metabolism. Additional areas of study involve cancer genomics and diagnostics, colorectal cancer treatments, and the role of gut microbiota in health.

H. Suryapranata has published research spanning multiple venues, with frequent publications in:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cancer Research
  • Cancer Epidemiology Biomarkers & Prevention
  • Nature Communications
  • American Journal of Clinical Nutrition

Their recent papers include:

  • "Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis," 2020, Nature Communications
  • "Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk," 2020, The American Journal of Human Genetics
  • "Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries," 2022, Nature Genetics
  • "Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study," 2020, BMC Medicine
  • "Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival," 2020, Nature Communications

Frequent collaborators of H. Suryapranata include:

  • Hermann Brenner
  • Michael Hoffmeister
  • Marc J. Gunter
  • Stefanie Brezina
  • Tabitha A. Harrison

The main scientific topics covered by H. Suryapranata's research demonstrate a strong focus on understanding genetic risk factors in colorectal cancer and its epidemiology alongside investigations into disease screening, diagnostics, and metabolic influences. Their multidisciplinary approach integrates molecular biology techniques and epidemiological data to explore cancer biology and potential clinical implications.

Best Publications

  • Time Delay to Treatment and Mortality in Primary Angioplasty for Acute Myocardial Infarction Every Minute of Delay Counts

    Giuseppe De Luca;Harry Suryapranata;Jan Paul Ottervanger;Elliott M. Antman

  • A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction.

    F. Zijlstra;M. J. De Boer;J. C. A. Hoorntje;S. Reiffers

  • Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.

    Giuseppe De Luca;Harry Suryapranata;Gregg W. Stone;David Antoniucci

  • Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial

    Arnoud Wj van't Hof;Jurriën ten Berg;Ton Heestermans;Thorsten Dill

  • Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty.

    Giuseppe De Luca;Harry Suryapranata;Felix Zijlstra;Arnoud W J van 't Hof

  • Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial.

    Daniel J F M Thuijs;A Pieter Kappetein;Patrick W Serruys;Friedrich-Wilhelm Mohr

  • Angiographic Assessment of Reperfusion in Acute Myocardial Infarction by Myocardial Blush Grade

    Jose P.S. Henriques;Felix Zijlstra;Arnoud W.J. van ‘t Hof;Menko-Jan de Boer

  • PexeLizumab for Acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial

    Paul W. Armstrong;N. Bett;D. Brieger;D. Chew

  • The Na^+/H^+ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction : Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial

    Uwe Zeymer;Harry Suryapranata;Jean Pierre Monassier;Grzegorz Opolski

  • Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Frequency, prediction, clinical course, management, and follow-up.

    P J de Feyter;M van den Brand;G J Laarman;R van Domburg

  • Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy.

    Menko-Jan de Boer;Jan-Paul Ottervanger;Arnoud W J van 't Hof;Jan C A Hoorntje

  • Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: The glucose-insulin-potassium study: a randomized trial☆

    Iwan C.C. van der Horst;Felix Zijlstra;Arnoud W.J. van 't Hof;Catharina Jacoba Maria Doggen

  • Prognostic Assessment of Patients With Acute Myocardial Infarction Treated With Primary Angioplasty Implications for Early Discharge

    Giuseppe De Luca;Harry Suryapranata;Arnoud W J van 't Hof;Menko-Jan de Boer

  • Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group.

    Carlos Miguel;Patrick Serruys;Peter Ruygrok;Harry Suryapranata

  • The effect of completeness of revascularization on event-free survival at one year in the arts trial

    Marcel J.B.M van den Brand;Benno J.W.M Rensing;Marie-angèle M Morel;David P Foley

  • Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty.

    Giuseppe De Luca;Arnoud W J van 't Hof;Menko-Jan de Boer;Jan Paul Ottervanger

  • Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial.

    Arnoud W. J. van 't Hof;Nicolette Ernst;Menko-Jan de Boer;Rob de Winter

  • Drug-Eluting vs Bare-Metal Stents in Primary Angioplasty: A Pooled Patient-Level Meta-analysis of Randomized Trials

    Giuseppe De Luca;Maurits T. Dirksen;Christian Spaulding;Henning Kelbæk

  • Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis

    Eliano Pio Navarese;Kenneth Tandjung;Bimmer Claessen;Felicita Andreotti

  • Long-Term Benefit of Primary Angioplasty as Compared with Thrombolytic Therapy for Acute Myocardial Infarction

    Felix Zijlstra;Jan C.A. Hoorntje;Menko-Jan De Boer;Stoffer Reifers

Frequent Co-Authors

Patrick W. Serruys
Patrick W. Serruys University of Galway
Pim J. de Feyter
Pim J. de Feyter Erasmus University Rotterdam
Petr Widimsky
Petr Widimsky Charles University
Alec Vahanian
Alec Vahanian Université Paris Cité
Ron T. van Domburg
Ron T. van Domburg Erasmus University Rotterdam
Johan H. C. Reiber
Johan H. C. Reiber Leiden University Medical Center
Felix Zijlstra
Felix Zijlstra Erasmus University Rotterdam
Peter de Jaegere
Peter de Jaegere Erasmus University Rotterdam
Jos R.T.C. Roelandt
Jos R.T.C. Roelandt Erasmus University Rotterdam
Keith D. Dawkins
Keith D. Dawkins Boston Scientific (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The field of Medicine in the USA offers a range of online degrees for students interested in healthcare careers beyond traditional medical school. With the growing demand for healthcare professionals, many accredited institutions now provide flexible options to earn advanced degrees from home.

For aspiring healthcare leaders, pursuing an affordable mha online can open doors to administrative roles in hospitals and clinics. Those interested in advanced nursing practice may consider enrolling in one of the best dnp programs online to achieve a Doctor of Nursing Practice degree.

Pharmacists looking for more flexibility can pursue an online pharmacist degree, which allows for continuing education without pausing professional commitments. Additionally, a him associate degree online can prepare students for careers in managing vital health records and information systems.

These pathways provide accessible options for those seeking to advance or pivot their healthcare careers with the convenience of online learning.

Best Scientists Citing H. Suryapranata

Trending Scientists

Recently Published Articles